

Ana-Iris Schiefer

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8883153/publications.pdf>

Version: 2024-02-01

50
papers

1,054
citations

430874

18
h-index

434195

31
g-index

51
all docs

51
docs citations

51
times ranked

2063
citing authors

#	ARTICLE	IF	CITATIONS
1	Functional Precision Medicine Provides Clinical Benefit in Advanced Aggressive Hematologic Cancers and Identifies Exceptional Responders. <i>Cancer Discovery</i> , 2022, 12, 372-387.	9.4	77
2	Splenectomy ameliorates portal pressure and anemia in animal models of cirrhotic and non-cirrhotic portal hypertension. <i>Advances in Medical Sciences</i> , 2022, 67, 154-162.	2.1	4
3	BRG1 and NPM-ALK Are Co-Regulated in Anaplastic Large-Cell Lymphoma; BRG1 Is a Potential Therapeutic Target in ALCL. <i>Cancers</i> , 2022, 14, 151.	3.7	2
4	Tumor cell budding in preoperative biopsies of esophageal and gastroesophageal junction carcinoma independently predicts survival in a grade-dependent manner. <i>Surgery</i> , 2022, 172, 567-574.	1.9	4
5	Tumour immune microenvironment in resected thymic carcinomas as a predictor of clinical outcome. <i>British Journal of Cancer</i> , 2022, 127, 1162-1171.	6.4	3
6	CDK4/CDK6 Inhibitors Synergize with Midostaurin, Avapritinib, and Nintedanib in Inducing Growth Inhibition in KIT D816V+ Neoplastic Mast Cells. <i>Cancers</i> , 2022, 14, 3070.	3.7	0
7	Core-binding factor acute myeloid leukemia with inv(16): Older age and high white blood cell count are risk factors for treatment failure. <i>International Journal of Laboratory Hematology</i> , 2021, 43, e19-e25.	1.3	6
8	Gain-of-function variants in SYK cause immune dysregulation and systemic inflammation in humans and mice. <i>Nature Genetics</i> , 2021, 53, 500-510.	21.4	56
9	Genomic Spectrum and Phenotypic Heterogeneity of Human IL-21 Receptor Deficiency. <i>Journal of Clinical Immunology</i> , 2021, 41, 1272-1290.	3.8	25
10	Secondary cytogenetic abnormalities in core-binding factor AML harboring inv(16) vs t(8;21). <i>Blood Advances</i> , 2021, 5, 2481-2489.	5.2	25
11	Co-occurrence of immature T-lymphoblastic lymphoma and acute myeloid leukemia—microenvironment-dependent lineage differentiation derived from a common progenitor?. <i>Journal of Hematopathology</i> , 2021, 14, 325-332.	0.4	0
12	Secondary basophilic leukemia in Ph-negative myeloid neoplasms: A distinct subset with poor prognosis. <i>Neoplasia</i> , 2021, 23, 1183-1191.	5.3	1
13	Influence of TP53 Mutation on Survival of Diffuse Large B-Cell Lymphoma in the CAR T-Cell Era. <i>Cancers</i> , 2021, 13, 5592.	3.7	9
14	High activation of STAT5A drives peripheral T-cell lymphoma and leukemia. <i>Haematologica</i> , 2020, 105, 435-447.	3.5	27
15	Myelomonocytic Skewing In Vitro Discriminates Subgroups of Patients with Myelofibrosis with A Different Phenotype, A Different Mutational Profile and Different Prognosis. <i>Cancers</i> , 2020, 12, 2291.	3.7	3
16	PD-L1 and HER2 Expression in Gastroesophageal Cancer: a Matched Case Control Study. <i>Pathology and Oncology Research</i> , 2020, 26, 2225-2235.	1.9	15
17	Heat shock protein 90 α in thymic epithelial tumors and non-thymomatous myasthenia gravis. <i>Oncolmmunology</i> , 2020, 9, 1756130.	4.6	6
18	Treatment Guided By Next Generation Functional Drug Screening Provides Clinical Benefit in Advanced Aggressive Hematological Malignancies: Final Evaluation of the Open Label, Single Arm Exalt Trial. <i>Blood</i> , 2020, 136, 2-4.	1.4	1

#	ARTICLE	IF	CITATIONS
19	PD-1 and PD1 expression in post-transplantation lymphoproliferative disease (PTLD) of childhood and adolescence: An inter- and intra-individual descriptive study covering the whole spectrum of PTLD categories. <i>Cancer Medicine</i> , 2019, 8, 4656-4668.	2.8	14
20	Transformed mucosa-associated lymphoid tissue lymphomas: A single institution retrospective study including polymerase chain reaction-based clonality analysis. <i>British Journal of Haematology</i> , 2019, 186, 448-459.	2.5	16
21	Chronic CD30 signaling in B cells results in lymphomagenesis by driving the expansion of plasmablasts and B1 cells. <i>Blood</i> , 2019, 133, 2597-2609.	1.4	14
22	Follistatin impacts Tumor Angiogenesis and Outcome in Thymic Epithelial Tumors. <i>Scientific Reports</i> , 2019, 9, 17359.	3.3	12
23	Clinical prognostic scores for patients with thymic epithelial tumors. <i>Scientific Reports</i> , 2019, 9, 18581.	3.3	6
24	Imatinib +/- Brentuximab Vedotin Induces Sustained Complete Remission in Chemotherapy-Resistant Anaplastic Large Cell Lymphoma Expressing PDGFR. <i>Blood</i> , 2019, 134, 4037-4037.	1.4	1
25	miR-150 downregulation contributes to the high-grade transformation of follicular lymphoma by upregulating FOXP1 levels. <i>Blood</i> , 2018, 132, 2389-2400.	1.4	45
26	Core-binding factor acute myeloid leukemia with t(8;21): Risk factors and a novel scoring system (I-CBF) Tj ETQo 0 0 rgBT /Overlo	2.8	17
27	Aggressive B-cell lymphomas in patients with myelofibrosis receiving JAK1/2 inhibitor therapy. <i>Blood</i> , 2018, 132, 694-706.	1.4	132
28	Prognostic and diagnostic impact of fibrinogen, neutrophil-to-lymphocyte ratio, and platelet-to-lymphocyte ratio on thymic epithelial tumors outcome. <i>Oncotarget</i> , 2018, 9, 21861-21875.	1.8	17
29	CCL2 is a KIT D816V-dependent modulator of the bone marrow microenvironment in systemic mastocytosis. <i>Blood</i> , 2017, 129, 371-382.	1.4	24
30	Impact of white blood cell counts at diagnosis and during follow-up in patients with essential thrombocythaemia and prefibrotic primary myelofibrosis. <i>British Journal of Haematology</i> , 2017, 179, 166-169.	2.5	18
31	Multicenter Evaluation of a Novel Automated Rapid Detection System of BRAF Status in Formalin-Fixed, Paraffin-Embedded Tissues. <i>Journal of Molecular Diagnostics</i> , 2016, 18, 370-377.	2.8	25
32	Incidence of intensive care unit admission, outcome and post intensive care survival in patients with diffuse large B-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2016, 57, 1831-1838.	1.3	23
33	Lymphovascular invasion of tumor cells in lymph node metastases has a negative impact on survival in esophageal cancer. <i>Surgery</i> , 2016, 160, 331-340.	1.9	26
34	Insights into the Pathogenesis of Anaplastic Large-Cell Lymphoma through Genome-wide DNA Methylation Profiling. <i>Cell Reports</i> , 2016, 17, 596-608.	6.4	55
35	Anaplastic large cell lymphoma arises in thymocytes and requires transient TCR expression for thymic egress. <i>Nature Communications</i> , 2016, 7, 10087.	12.8	65
36	Transformed mycosis fungoides: bridging to allogeneic stem cell transplantation with brentuximab vedotin. <i>Leukemia and Lymphoma</i> , 2016, 57, 206-208.	1.3	12

#	ARTICLE	IF	CITATIONS
37	Prefibrotic Primary Myelofibrosis As an Entity Distinct from Other Philadelphia-Chromosome Negative Myeloproliferative Neoplasms - Data from the Austrian Reclassification Project. <i>Blood</i> , 2016, 128, 4252-4252.	1.4	2
38	Cooperation of ETV6/RUNX1 and BCL2 enhances immunoglobulin production and accelerates glomerulonephritis in transgenic mice. <i>Oncotarget</i> , 2016, 7, 12191-12205.	1.8	6
39	Survival in Essential Thrombocythemia and Prefibrotic Primary Myelofibrosis - Correlation of Clinical Phenotype with Histomorphological Diagnosis. <i>Blood</i> , 2016, 128, 1932-1932.	1.4	0
40	Evaluation of tyrosine kinase receptors in brain metastases of clear cell renal cell carcinoma reveals cMet as a negative prognostic factor. <i>Histopathology</i> , 2015, 67, 799-805.	2.9	10
41	Impact of Single or Combined Genomic Alterations of TP53, MYC, and BCL2 on Survival of Patients With Diffuse Large B-Cell Lymphomas. <i>Medicine (United States)</i> , 2015, 94, e2388.	1.0	24
42	Oncogenic role of miR-155 in anaplastic large cell lymphoma lacking the t(2;5) translocation. <i>Journal of Pathology</i> , 2015, 236, 445-456.	4.5	49
43	High Expression of AF1q Is an Adverse Prognostic Factor in Multiple Myeloma Patients Treated with Autologous Stem Cell Transplantation. <i>Blood</i> , 2015, 126, 5321-5321.	1.4	0
44	Clinical Impact of Bone Marrow Morphology for the Diagnosis of Essential Thrombocythemia: Comparison Between the British Standards (BCSH) and the WHO Criteria. <i>Blood</i> , 2015, 126, 2816-2816.	1.4	0
45	Expression of RAGE and HMGB1 in Thymic Epithelial Tumors, Thymic Hyperplasia and Regular Thymic Morphology. <i>PLoS ONE</i> , 2014, 9, e94118.	2.5	30
46	Local and Systemic RAGE Axis Changes in Pulmonary Hypertension: CTEPH and iPAH. <i>PLoS ONE</i> , 2014, 9, e106440.	2.5	23
47	Lenalidomide induced response in a patient with follicular lymphoma of the skin and an anti-rituximab-antibody. <i>Memo - Magazine of European Medical Oncology</i> , 2013, 6, 123-126.	0.5	1
48	PDGFR blockade is a rational and effective therapy for NPM-ALK-driven lymphomas. <i>Nature Medicine</i> , 2012, 18, 1699-1704.	30.7	113
49	Extranodal marginal zone lymphoma of the CNS arising after a long-standing history of atypical white matter disease. <i>Leukemia Research</i> , 2012, 36, e155-e157.	0.8	10
50	A New Prognostic Score for Aggressive B-Cell Lymphoma with C-MYC Translocation Integrating Clinical and Genetic Features.. <i>Blood</i> , 2012, 120, 2685-2685.	1.4	0